| Hazard Information | Back Directory | [Description]
Telisotuzumab vedotin (Teliso-V) is an antibody drug conjugate that targets the
MET receptor. | [Clinical Use]
In the first in-human phase I trial for Teliso-V, NSCLC patients with
MET-overexpressing tumors received monotherapy. The results of this innovative
trial indicated favorable safety and tolerability responses and also showed promising
antitumor activity in NSCLC patients with MET overexpression. |
|
| Company Name: |
DC Chemicals
|
| Tel: |
021-58447131 13564518121 |
| Website: |
https://www.chemicalbook.com/ShowSupplierProductsList927327/0.htm |
| Company Name: |
bioleaper
|
| Tel: |
18601717983 |
| Website: |
www.bioleaper.com/ |
|